Comments
Lupin on Thursday said it has received final approval from the US health regulator to market its Clonidine Hydrochloride extended release tablets used for treatment of attention deficit hyperactivity disorder. The company has received USFDA’s final approval to market the tablets in the strength of 0.1 mg, Lupin said in a notice to the stock exchanges. Shares of Lupin will remain in focus, as investors are likely to closely watch the development.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.